This study was conducted among women who had previously received alendronate for 3 to 6 years during the Fracture Intervention Trial (FIT). Participants in the FLEX study were randomly assigned to receive alendronate (either 5 or 10 mg/day) or matching placebo during the next 5 years, in order to evaluate the effects of continuing or discontinuing alendronate treatment on bone mineral density and biochemical markers of bone turnover.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,099
Total hip bone mineral density (BMD)
BMD of femoral neck, trochanter, and lumbar spine
Biochemical markers of bone turnover
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.